Hepatitis Monthly
Abbas Rezaianzadeh1, Abbas Rezaianzadeh1, Jafar Hasanzadeh1, Jafar Hasanzadeh1, 
Abbas Alipour2,*, Abbas Alipour1,*, Mohamed Ali Davarpanah1, Mohamed Ali Davarpanah1, Abdorreza Rajaeifard1, Abdorreza Rajaeifard1, Seyed Hamid Reza Tabatabaee1, Seyed Hamid Reza Tabatabaee1HIV and HCV infections are basic issues of many health systems. Since HIV and HCV are transmitted similarly, it is common to become infected by them simultaneously. No consensus exists on the effect of HCV infection on the survival of HIV-infected patients.
This study aimed to investigate the issue in a relatively large cohort of patients who had a high prevalence of this coinfection in Shiraz (South of Iran).
In this historical cohort study, we evaluated the survival time of 1338 HIV-infected individuals who had been referred to a behavioral consultation center in Shiraz over 10 years (from April 2001 to July 2011). Kaplan-Meier method and log-rank test were used to investigate patient survival and compare their survival curves, respectively. Moreover, Cox proportional hazards model was used to examine the effect of HCV infection on patient survival after control for age, sex, having the injection drug use (IDU) risk factor, CD4 count at baseline, more than a 30% decline in CD4 cell count, and highly active antiretroviral therapy (HAART).
In our cohort, 1044 patients (78.03%) were infected by HCV. The median follow-up was 43.48 months (95% CI = 61.18-26.63). The median survival time in HCV-infected and uninfected patients was 163.8 and 194.8 months, respectively (P = 0.039). After controlling for other covariates, HCV infection increased the mortality rate 2.13 times more in HCV-infected patients than HCV -uninfected patients (CI: 95%; 1.1-4.52).
HCV infection increases AIDS-related deaths. To control HCV infection and transmission and eliminate HCV, timely diagnosis and treatment and serious harm reduction programs must be implemented.
© 2012, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Grzeszczuk A, Wandalowicz AD, Jaroszewicz J, Flisiak R. Prevalence and Risk Factors of HCV/HIV Co-Infection and HCV Genotype Distribution in North-Eastern Poland. Hepat Mon. 2015;15(7):e27740. doi: https://doi.org/10.5812/hepatmon.27740v2
Altuntas Aydin O, Yemisen M, Kumbasar Karaosmanoglu H, Sargin F, Gunduz A, et al. Low Prevalence of Hepatitis C Virus Infection Among HIV-Positive Patients: Data From a Large-Scale Cohort Study in Istanbul, Turkey. Hepat Mon. 2014;14(8):e18128. doi: https://doi.org/10.5812/hepatmon.18128
Afzali H, Momen-Heravi M, Farokhzad A. Epidemiological Distribution and Genotype Characterization of the Hepatitis C Virus Among HIV Patients in Kashan, Iran. Hepat Mon. 2016;16(7):e30459. doi: https://doi.org/10.5812/hepatmon.30459
Babaei AH, Safarpour AR, Fattahi MR, Ahmadi V. Epidemiology of Hepatitis C Virus Infection Among 1,959 Patients in Shiraz, Southern Iran, Between 1991 and 2016. Arch Clin Infect Dis. 2020;15(1):e98849. doi: https://doi.org/10.5812/archcid.98849
Ataei B, Tayeri K, Farajzadegan Z, Babak A, Kassaian N. Hepatitis B and C among Patients Infected with Human Immunodeficiency Virus in Isfahan, Iran: Seroprevalence and Associated Factors. Hepat Mon. 2010;10(3):. doi:
Ordering Reprints
Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC
Author(s):
